Gilead Sciences Inc. (GILD) Given Outperform Rating at Robert W. Baird
Gilead Sciences Inc. (NASDAQ:GILD)‘s stock had its “outperform” rating reaffirmed by investment analysts at Robert W. Baird in a research report issued on Tuesday. They currently have a $122.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $135.00. Robert W. Baird’s price target suggests a potential upside of 62.15% from the company’s previous close.
A number of other equities analysts also recently commented on GILD. Morgan Stanley restated a “hold” rating and issued a $103.00 price objective on shares of Gilead Sciences in a report on Wednesday, June 15th. Jefferies Group restated a “hold” rating and issued a $97.00 price objective on shares of Gilead Sciences in a report on Friday, July 15th. Maxim Group restated a “hold” rating on shares of Gilead Sciences in a report on Sunday, July 10th. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $105.06 price objective on the stock in a report on Monday, May 2nd. Finally, Mizuho restated a “buy” rating and issued a $130.00 price objective on shares of Gilead Sciences in a report on Sunday, April 10th. Ten equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the company’s stock. Gilead Sciences has a consensus rating of “Buy” and an average price target of $104.71.
Gilead Sciences (NASDAQ:GILD) traded down 1.27% during mid-day trading on Tuesday, reaching $75.24. 11,149,150 shares of the company traded hands. The company has a market capitalization of $99.29 billion, a P/E ratio of 6.60 and a beta of 1.10. Gilead Sciences has a 52-week low of $74.92 and a 52-week high of $111.11. The stock has a 50 day moving average price of $78.95 and a 200-day moving average price of $85.05.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/09/gilead-sciences-inc-gild-given-outperform-rating-at-robert-w-baird.html
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.02 by $0.06. The business earned $7.78 billion during the quarter, compared to analyst estimates of $7.80 billion. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The firm’s revenue was down 5.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.15 earnings per share. Analysts expect that Gilead Sciences will post $11.76 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 29th. Stockholders of record on Friday, September 16th were issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 2.50%. The ex-dividend date of this dividend was Wednesday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 16.56%.
In other Gilead Sciences news, EVP Paul Rutherford Carter sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $79.81, for a total value of $159,620.00. Following the sale, the executive vice president now owns 64,122 shares in the company, valued at approximately $5,117,576.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John C. Martin sold 100,000 shares of the business’s stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $80.50, for a total value of $8,050,000.00. Following the completion of the sale, the insider now owns 4,119,727 shares in the company, valued at approximately $331,638,023.50. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. Advisory Services Network LLC boosted its stake in Gilead Sciences by 7.5% in the third quarter. Advisory Services Network LLC now owns 37,128 shares of the biopharmaceutical company’s stock valued at $2,938,000 after buying an additional 2,605 shares during the last quarter. Trust Co. of Oklahoma boosted its stake in Gilead Sciences by 10.1% in the third quarter. Trust Co. of Oklahoma now owns 6,467 shares of the biopharmaceutical company’s stock valued at $512,000 after buying an additional 593 shares during the last quarter. Lawson Kroeker Investment Management Inc. NE boosted its stake in Gilead Sciences by 23.9% in the third quarter. Lawson Kroeker Investment Management Inc. NE now owns 129,329 shares of the biopharmaceutical company’s stock valued at $10,233,000 after buying an additional 24,975 shares during the last quarter. Founders Financial Securities LLC purchased a new stake in Gilead Sciences during the third quarter valued at approximately $845,000. Finally, F&V Capital Management LLC boosted its stake in Gilead Sciences by 3.7% in the third quarter. F&V Capital Management LLC now owns 78,410 shares of the biopharmaceutical company’s stock valued at $6,204,000 after buying an additional 2,775 shares during the last quarter. Hedge funds and other institutional investors own 77.94% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.